Depression: A Clinical Guide for South Africans

Depression is one of the most common clinical conditions in South African general practice, and one of the most treatable. National survey data (SASH, the South African Stress and Health study) estimate that 9.7% of adults will experience a major depressive episode at some point in their lives, with a 12-month prevalence of 4.9%. Yet fewer than 25% of South Africans with probable depression receive any evidence-based treatment, and recent modelling suggests that "minimally adequate treatment" reaches under 5% of the affected population. This guide covers how depression actually presents, how it is diagnosed, what treatment involves, and when it is time to seek help.

What depression actually is

Depression is a clinical syndrome characterised by persistent low mood and loss of interest or pleasure, accompanied by physical, cognitive, and behavioural changes. The DSM-5 criteria for a major depressive episode require at least five of the following symptoms, for at least two weeks, with at least one being low mood or anhedonia:

• Depressed mood most of the day, nearly every day
• Markedly diminished interest or pleasure in most activities
• Significant appetite or weight change
• Insomnia or hypersomnia
• Psychomotor agitation or retardation
• Fatigue or loss of energy
• Feelings of worthlessness or excessive, inappropriate guilt
• Diminished concentration, indecisiveness
• Recurrent thoughts of death or suicidal ideation

The symptoms must cause clinically significant distress or functional impairment and must not be better explained by another medical condition, substance, or medication.

Depression is not the same as sadness. Sadness is a normal response to loss, disappointment, or difficulty; it is proportional, time-limited, and does not usually interfere with daily function. Clinical depression is a persistent state that continues regardless of external circumstances and often feels qualitatively different. Many patients describe it less as "being sad" and more as being flat, disconnected, or empty.

How depression presents

Presentations vary widely. Some patients recognise their mood as depressed. Many do not, and present instead with:

• Persistent fatigue that rest does not fix
• Sleep disturbance (early-morning waking is classic; excessive sleep also common)
• Appetite change and unintentional weight loss or gain
• Concentration problems at work, reading that does not stick, indecision
• Irritability, particularly in men and adolescents who may deny "low mood" but describe feeling constantly on edge
• Unexplained physical symptoms: headaches, back pain, gastrointestinal complaints
• Loss of libido, which sometimes precedes the emotional awareness of depression
• Social withdrawal, avoiding friends and family, cancelling plans

In older adults, depression often presents as cognitive complaints or physical symptoms rather than mood. In men, it more often looks like irritability, anger, or increased alcohol use. In women, it more often looks like tearfulness, guilt, and anxiety symptoms. None of these is more or less "valid" than the others.

Depression in South Africa: the treatment gap

The gap between how common depression is and how rarely it is treated is large. SASH found that only 8% of adults with lifetime major depression had spoken to a psychiatrist in the past 12 months. Global estimates place "minimally adequate treatment" for depression in sub-Saharan Africa at around 2%. South Africa performs better than the regional average but remains below 5%.

Reasons the gap exists include:

• Stigma around mental illness and help-seeking
• Limited access to mental health services, especially in rural areas
• Under-recognition of depression in general practice
• Lack of awareness that depression is treatable
• Financial barriers where public-sector capacity is strained
• Cultural idioms of distress that do not map neatly onto DSM criteria

One consequence of this gap is that many patients present to primary care with physical symptoms (fatigue, pain, insomnia) that are the outward expression of depression. Recognising the pattern is the first step. Treating it is the second.

How depression is diagnosed

Depression is a clinical diagnosis. There is no blood test or scan that confirms it. Diagnosis depends on a structured clinical interview against the DSM-5 criteria, supported by validated screening tools.

A proper assessment typically includes:

• Detailed history. Symptom duration, severity, prior episodes, functional impact, triggers, family history of depression or bipolar disorder, medical conditions, medications, alcohol and substance use.
• Mental state examination. Including mood, affect, thought content (especially any suicidal ideation), cognition, and insight.
• Screening tools. Validated instruments such as the Patient Health Questionnaire (PHQ-9) help standardise severity assessment and track response to treatment. South African primary-care validation of the PHQ-9 shows good sensitivity and specificity, with minor local adaptations for multilingual and high-HIV-burden settings. Tool scores support clinical judgement; they do not replace it.
• Screening for bipolar disorder. Any history of manic or hypomanic episodes (elevated mood, decreased need for sleep, racing thoughts, risky behaviour) changes management substantially. Antidepressant monotherapy in undiagnosed bipolar disorder can precipitate mania.
• Medical differential. Hypothyroidism, vitamin B12 and vitamin D deficiency, anaemia, sleep apnoea, and certain medications (corticosteroids, beta-blockers, interferon) can mimic depression. Baseline bloods are often appropriate.
• Suicide risk assessment. Explicit, direct, and non-judgemental. "Have you had thoughts of ending your life?" This question does not cause suicide. It permits honest conversation and enables appropriate care.

Evidence-based treatment

Depression is one of the best-studied conditions in medicine. First-line options are supported by large bodies of evidence and clear clinical guidelines.

Antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy for most adults. The 2018 Cipriani et al. network meta-analysis of 522 trials and 116,477 participants confirmed that all antidepressants are more effective than placebo, with several showing particular efficacy and acceptability:

• SSRIs (sertraline, escitalopram, fluoxetine, citalopram, paroxetine) are generally first choice. Escitalopram ranks consistently among the most effective and best-tolerated SSRIs.
• SNRIs (venlafaxine, duloxetine) show slightly higher short-term efficacy in some analyses but more discontinuation due to side effects; they are useful when pain or fatigue is prominent.
• Mirtazapine can be useful when sleep disturbance and appetite loss are prominent, accepting weight gain and sedation as trade-offs.
• Bupropion has a different mechanism (dopamine-noradrenaline), useful when sexual side effects or weight gain with SSRIs are a concern; less evidence and more seizure risk.
• Tricyclic antidepressants and MAOIs retain a role in treatment-resistant cases but are not first-line.

Response is gradual. Meaningful improvement typically appears at 2 to 4 weeks; full response usually at 6 to 8 weeks at an adequate dose. Partial improvement by 4 weeks is a reasonable early signal. Lack of any improvement at 6 to 8 weeks prompts reassessment: diagnosis, dose, adherence, or drug switch.

After remission of a first episode, antidepressants are typically continued for at least 6 months, reducing relapse risk by about 70% compared with placebo (Geddes et al. 2003 meta-analysis). For recurrent depression (two or more prior episodes), treatment is often continued for 12 months or longer.

SSRI side effects are typically mild and transient: early nausea, headache, insomnia, or sexual side effects. Serious adverse events are rare. Suicide-risk monitoring is appropriate in the first 4 weeks of treatment, particularly in younger adults.

Psychological therapy

Cognitive behavioural therapy (CBT) is the best-evidenced psychotherapy for depression and broadly comparable to antidepressant medication in acute treatment. A 2023 JAMA network meta-analysis of 101 randomised trials and 11,901 patients found no significant difference in short-term efficacy between CBT and antidepressants as monotherapies, with response rates around 50% for both.

Combination treatment (CBT plus medication) produces modestly better acute outcomes (response rates around 65%) and substantially better relapse prevention than medication alone. For moderate to severe depression, combination is a reasonable default.

Other evidence-based psychotherapies include interpersonal therapy (IPT) and behavioural activation. For mild depression, structured behavioural activation alone is often sufficient.

Lifestyle and exercise

Exercise is not a "nice to have". A 2024 BMJ network meta-analysis of 218 trials and 14,170 participants found moderate-intensity aerobic exercise produces effect sizes comparable to antidepressants for non-severe depression. Walking, jogging, yoga, strength training, and mixed aerobic activities all show benefit; supervised group formats tend to work better than unsupervised solo exercise.

For mild to moderate depression, a structured exercise programme is an evidence-based first-line option. For moderate to severe depression, it is a useful adjunct to medication and therapy, not a replacement.

Sleep regularity, reduced alcohol intake, and maintained social connection are all clinically meaningful. These interventions are free, accessible, and underused.

When specialist referral is needed

Most depression is well-managed in primary care. Psychiatrist referral is appropriate for:

• Severe depression with marked functional impairment, psychomotor retardation, or inability to self-care.
• Psychotic features (delusions of guilt, worthlessness, or nihilism; hallucinations). This is a medical emergency requiring urgent assessment and usually combined antipsychotic and antidepressant therapy.
• Active suicidality with plan, intent, or recent attempts. Immediate safety takes priority.
• Bipolar spectrum features, including any past manic or hypomanic episodes. Antidepressant monotherapy in bipolar disorder can trigger mania and worsen the long-term course.
• Treatment-resistant depression, defined as inadequate response after two adequate antidepressant trials (correct dose, 6 to 8 weeks each).
• Significant psychiatric comorbidity: active substance use disorder, severe personality disorder, eating disorder, or post-traumatic stress disorder.
• Complex medical context, including advanced HIV, cardiovascular disease, or pregnancy, where drug interactions and monitoring complexity justify specialist input.

At NeoHealth, Dr Chellan conducts depression assessments and manages depression at GP level as part of his mental health scope. Cases that require specialist-led care are referred to a psychiatrist with a clear handover letter.

Crisis support

If you are in crisis, or have thoughts of harming yourself, help is available now:

• South African Depression and Anxiety Group (SADAG): 0800 567 567 (24 hours, free, confidential)
• Lifeline: 0861 322 322
• Suicide Crisis Line: 0800 567 567 / SMS 31393
• Your nearest emergency unit if you are in immediate danger

You do not need to wait until things are "bad enough". Reaching out earlier leads to better outcomes.

Booking an assessment at NeoHealth

For depression assessment, medication management, CBT coordination, or ongoing follow-up, book a consultation with Dr Chellan at NeoHealth as part of our mental health service. Routine reviews, dose checks, and script renewals can also be done as telehealth consultations once an in-person diagnosis is in place. For crisis situations, go to your nearest emergency unit or call SADAG on 0800 567 567 immediately.

Discovery Health members with a clinical diagnosis of episodic major depression who meet entry criteria can be enrolled on the Mental Health Care Programme at NeoHealth. The programme covers GP consultations, antidepressant medication, referral to psychotherapy, and access to internet-based cognitive behavioural therapy.

For related topics, see Anxiety: symptoms, treatment, and when to seek help.

Sources and references

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision. APA 2022 (DSM-5-TR).
• Williams DR et al. SASH. Twelve-month mental disorders in South Africa: prevalence, service use and demographic correlates in the population-based South African Stress and Health Study. Psychological Medicine 2008 (PubMed).
• Cipriani A et al.. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet 2018 (PubMed).
• Cuijpers P et al.. Cognitive behaviour therapy vs antidepressants for major depressive disorder in adults: network meta-analysis. JAMA 2023 (PubMed).
• Geddes JR et al.. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. The Lancet 2003 (PubMed).
• Noetel M et al.. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ 2024 (PubMed).
• NICE. Depression in adults: treatment and management NG222. NICE 2022.

Content on this page is based on these sources and current clinical practice at NeoHealth. It is general health information, not personalised medical advice. Book a consultation for individual assessment.